VolitionRx gets Lind waiver for unlimited ATM sales; conversion price set at $0.44

VOLITIONRX LTD

Lind consents to all ATM sales, removing $10M annual cap; waives related defaults and remedies under Purchase Agreement and Notes.
Conversion price of $7.5M (May 2025) and $2.4M (Jan 2026) senior secured notes fixed at $0.44; warrant exercise price set at $0.572.
Lind waives anti-dilution adjustments to Notes/Warrants for ATM sales after Aug 28, 2026; prior adjustments accounted for through that date.
Company still must apply 20% of ATM proceeds (above exempted amounts) toward note repayment per Section 5.7 of Purchase Agreement.
Waiver dated Sept 2, 2026; CEO Cameron Reynolds signed for VolitionRx.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.